367 related articles for article (PubMed ID: 28540607)
41. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
[TBL] [Abstract][Full Text] [Related]
42. S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis.
Gohar F; Anink J; Moncrieffe H; Van Suijlekom-Smit LWA; Prince FHM; van Rossum MAJ; Dolman KM; Hoppenreijs EPAH; Ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Foell D; Holzinger D
J Rheumatol; 2018 Apr; 45(4):547-554. PubMed ID: 29335345
[TBL] [Abstract][Full Text] [Related]
43. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy.
Aikawa NE; França IL; Ribeiro AC; Sallum AM; Bonfa E; Silva CA
Vaccine; 2015 Jan; 33(5):604-9. PubMed ID: 25554240
[TBL] [Abstract][Full Text] [Related]
44. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis.
De Sanctis S; Marcovecchio ML; Gaspari S; Del Torto M; Mohn A; Chiarelli F; Breda L
J Rheumatol; 2013 Jun; 40(6):943-8. PubMed ID: 23547210
[TBL] [Abstract][Full Text] [Related]
45. Biologics in juvenile idiopathic arthritis: a narrative review.
Vanoni F; Minoia F; Malattia C
Eur J Pediatr; 2017 Sep; 176(9):1147-1153. PubMed ID: 28725955
[TBL] [Abstract][Full Text] [Related]
46. Incidence of herpes zoster infections in juvenile idiopathic arthritis patients.
Nimmrich S; Horneff G
Rheumatol Int; 2015 Mar; 35(3):465-70. PubMed ID: 25583050
[TBL] [Abstract][Full Text] [Related]
47. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis.
Tynjälä P; Lahdenne P; Vähäsalo P; Kautiainen H; Honkanen V
Ann Rheum Dis; 2006 Aug; 65(8):1044-9. PubMed ID: 16449314
[TBL] [Abstract][Full Text] [Related]
48. Effect of etanercept on refractory systemic-onset juvenile idiopathic arthritis.
Hu X; Yuan F; Zhang J; Yin L; Li BR; Jin YL
World J Pediatr; 2016 Feb; 12(1):96-102. PubMed ID: 25754755
[TBL] [Abstract][Full Text] [Related]
49. Enthesitis-related arthritis is the most common category of juvenile idiopathic arthritis in Taiwan and presents persistent active disease.
Shih YJ; Yang YH; Lin CY; Chang CL; Chiang BL
Pediatr Rheumatol Online J; 2019 Aug; 17(1):58. PubMed ID: 31443722
[TBL] [Abstract][Full Text] [Related]
50. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis.
Wallace CA; Giannini EH; Spalding SJ; Hashkes PJ; O'Neil KM; Zeft AS; Szer IS; Ringold S; Brunner HI; Schanberg LE; Sundel RP; Milojevic D; Punaro MG; Chira P; Gottlieb BS; Higgins GC; Ilowite NT; Kimura Y; Hamilton S; Johnson A; Huang B; Lovell DJ;
Arthritis Rheum; 2012 Jun; 64(6):2012-21. PubMed ID: 22183975
[TBL] [Abstract][Full Text] [Related]
51. Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study.
Levälampi T; Kärki J; Rebane K; Vähäsalo P; Malin M; Kröger L; Grönlund MM; Backström M; Pohjankoski H; Kautiainen H; Jokiranta S; Aalto K
Pediatr Rheumatol Online J; 2023 Mar; 21(1):27. PubMed ID: 36949461
[TBL] [Abstract][Full Text] [Related]
52. Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept.
Öman A; Dicksved J; Engstrand L; Berntson L
Pediatr Rheumatol Online J; 2021 Apr; 19(1):55. PubMed ID: 33902613
[TBL] [Abstract][Full Text] [Related]
53. Clinical trial of etanercept tapering in juvenile idiopathic arthritis during remission.
Cai Y; Liu X; Zhang W; Xu J; Cao L
Rheumatol Int; 2013 Sep; 33(9):2277-82. PubMed ID: 23468176
[TBL] [Abstract][Full Text] [Related]
54. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
Perrotta FM; Marchesoni A; Lubrano E
J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
[TBL] [Abstract][Full Text] [Related]
55. Influence of etanercept on leptin and ghrelin secretion in children with juvenile idiopathic arthritis.
Maciejewska-Paszek I; Grochowska-Niedworok E; Siwiec A; Gruenpeter A; Dul L; Irzyniec T
J Int Med Res; 2017 Apr; 45(2):525-532. PubMed ID: 28415953
[TBL] [Abstract][Full Text] [Related]
56. Etanercept plus standard therapy for Wegener's granulomatosis.
Wegener's Granulomatosis Etanercept Trial (WGET) Research Group
N Engl J Med; 2005 Jan; 352(4):351-61. PubMed ID: 15673801
[TBL] [Abstract][Full Text] [Related]
57. Serum osteopontin as a predictive marker of responsiveness to methotrexate in juvenile idiopathic arthritis.
Masi L; Ricci L; Zulian F; Del Monte F; Simonini G; Capannini S; De Martino M; Brandi ML; Falcini F
J Rheumatol; 2009 Oct; 36(10):2308-13. PubMed ID: 19684155
[TBL] [Abstract][Full Text] [Related]
58. Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study.
Gaubitz M; Göttl KH; Behmer O; Lippe R; Meng T; Löschmann PA
Clin Rheumatol; 2017 Sep; 36(9):1989-1996. PubMed ID: 28756532
[TBL] [Abstract][Full Text] [Related]
59. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
Horneff G; De Bock F; Foeldvari I; Girschick HJ; Michels H; Moebius D; Schmeling H;
Ann Rheum Dis; 2009 Apr; 68(4):519-25. PubMed ID: 18413440
[TBL] [Abstract][Full Text] [Related]
60. Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop?
Foell D; Frosch M; Schulze zur Wiesch A; Vogl T; Sorg C; Roth J
Ann Rheum Dis; 2004 Feb; 63(2):206-8. PubMed ID: 14722212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
